» Articles » PMID: 24647776

Role of Breast Surgery in BRCA Mutation Carriers

Overview
Publisher Karger
Date 2014 Mar 21
PMID 24647776
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

BRCA mutation carriers have a life-long breast cancer risk between 55 and 85% and a high risk of developing breast cancer at a very young age, depending on the type of mutation. The risk of developing contralateral breast cancer after a first breast cancer is elevated up to 65%, especially in case of BRCA1 mutation and young age at the first breast cancer. Since bilateral prophylactic mastectomy is associated with a risk reduction of 90-95% of developing primary or contralateral breast cancer, this option is a key point within the counseling process for patient information and shared decision-making of mutation carriers. Although the local control after breast-conserving therapy in mutation carriers seems to be comparable to that of sporadic breast cancer patients, individual patient information and counseling should include all alternative procedures of oncologically adequate mastectomy techniques and immediate reconstruction. Excellent cosmetic results, high levels of life quality, and good patient acceptance can be achieved with the recent developments in reconstructive surgery of the breast.

Citing Articles

Breast cancer characteristics and surgery among women with Li-Fraumeni syndrome in Germany-A retrospective cohort study.

Rippinger N, Fischer C, Sinn H, Dikow N, Sutter C, Rhiem K Cancer Med. 2021; 10(21):7747-7758.

PMID: 34569185 PMC: 8559485. DOI: 10.1002/cam4.4300.


Surgery for , TP53 and PALB2: a literature review.

Song C, Teo S, Taib N, Yip C Ecancermedicalscience. 2018; 12:863.

PMID: 30174725 PMC: 6113980. DOI: 10.3332/ecancer.2018.863.


Determinant of long-term quality of life: surgery in breast cancer treatment.

Kuhn T Breast Care (Basel). 2014; 7(5):361-2.

PMID: 24647773 PMC: 3518939. DOI: 10.1159/000343942.

References
1.
Imyanitov E, Moiseyenko V . Drug therapy for hereditary cancers. Hered Cancer Clin Pract. 2011; 9(1):5. PMC: 3171323. DOI: 10.1186/1897-4287-9-5. View

2.
Skytte A, Gerdes A, Andersen M, Sunde L, Brondum-Nielsen K, Waldstrom M . Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing. Clin Genet. 2010; 77(4):342-9. DOI: 10.1111/j.1399-0004.2009.01329.x. View

3.
Kirova Y, Savignoni A, Sigal-Zafrani B, De la Rochefordiere A, Salmon R, This P . Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature. Breast Cancer Res Treat. 2009; 120(1):119-26. DOI: 10.1007/s10549-009-0685-6. View

4.
Dieterich M, Dieterich H, Timme S, Reimer T, Gerber B, Stubert J . Using a titanium-coated polypropylene mesh (TiLOOP(®) Bra) for implant-based breast reconstruction: case report and histological analysis. Arch Gynecol Obstet. 2012; 286(1):273-6. DOI: 10.1007/s00404-012-2253-2. View

5.
Reynolds C, Davidson J, Lindor N, Glazebrook K, Jakub J, Degnim A . Prophylactic and therapeutic mastectomy in BRCA mutation carriers: can the nipple be preserved?. Ann Surg Oncol. 2011; 18(11):3102-9. DOI: 10.1245/s10434-011-1908-8. View